By potentially downregulating TGF-1, AHK-Cu may alter these cellular processes, possibly affecting cell growth and the immune response at a cellular level
However, Tang et al
Intracellular NAD+ depletion confers a priming signal for NLRP3 inflammasome activation

GHK-Cu Medicare Advantage Coverage: What You Need to Know in 2026 At a glance Medicare Advantage coverage / not covered under any current MAPD plan FDA approval status / no FDA-approved GHK-Cu drug product exists Average compounded cost / approximately $140 per month from 503A pharmacies Branded product / none on the market as of 2026 Insurance coverage broadly / no commercial or government payer covers GHK-Cu Manufacturer coupon / not applicable (no branded manufacturer) HSA/FSA eligibility / may qualify with a Letter of Medical Necessity Common supply form / injectable vial, topical serum, or subcutaneous formulation Compounding pharmacy type / 503A (patient-specific) with valid prescription Typical prescription requirement / yes, a licensed provider must prescribe Why Medicare Advantage Does Not Cover GHK-Cu Medicare Advantage plans, also called Medicare Part C, bundle hospital (Part A), outpatient (Part B), and usually prescription drug (Part D) benefits into a single managed-care package

Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG